Prospective Sinonasal Cancer Multi-institution Study

Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04755855

Enrollment

200

Registered

2021-02-16

Start date

2021-01-01

Completion date

2031-01-01

Last updated

2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinonasal Carcinoma

Brief summary

This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Days to 99 Years

Healthy volunteers

Inclusion criteria

* Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive) * Patients with a diagnosis of sinonasal cancer * Patients undergoing treatment at Mayo Clinic

Exclusion criteria

* Healthy individuals * Unwilling to sign the informed consent

Design outcomes

Primary

Measure	Time frame
Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival	Through study completion, an average of 5 years

Secondary

Measure	Time frame
Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22)	Through study completion, an average of 5 years
Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles	Through study completion, an average of 5 years

Countries

United States

Contacts

CONTACTClinical Trials Referral Office

mayocliniccancerstudies@mayo.edu855-776-0015

PRINCIPAL_INVESTIGATORJake Eide, MD

Mayo Clinic

Outcome results